Detection of Circulating Tumor Cells in Renal Cell Carcinoma: Disease Stage Correlation and Molecular Characterization

The presence of circulating tumor cells (CTCs) in patients with solid tumors is associated with poor prognosis. However, there are limited data concerning the detection of CTCs in renal cell cancer (RCC). The aim of this study is to evaluate the presence of CTCs in peripheral blood of patients with RCC undergoing surgery (n = 186). CTCs were tested before and after surgery as well as during the follow-up period afterwards. In total 495 CTC testing in duplicates were provided. To enrich CTCs, a size-based separation protocol and tube MetaCell® was used. CTCs presence was evaluated by single cell cytomorphology based on vital fluorescence microscopy. Additionally, to standardly applied fluorescence stains, CTCs viability was controlled by mitochondrial activity. CTCs were detected independently on the sampling order in up to 86.7% of the tested blood samples in patients undergoing RCC surgery. There is higher probability of CTC detection with growing tumor size, especially in clear cell renal cell cancer (ccRCC) cases. Similarly, the tumor size corresponds with metastasis presence and lymph node positivity and CTC detection. This paper describes for the first-time successful analysis of viable CTCs and their mitochondria as a part of the functional characterization of CTCs in RCC.

Download Full-text

Development of a Highly Sensitive Technique for Capturing Renal Cell Cancer Circulating Tumor Cells

Diagnostics ◽

10.3390/diagnostics9030096 ◽

2019 ◽

Vol 9 (3) ◽

pp. 96 ◽

Cited By ~ 4

Author(s):

Naoe ◽

Kusaka ◽

Ohta ◽

Hasebe ◽

Unoki ◽

...

Keyword(s):

Tumor Cells ◽

Circulating Tumor Cells ◽

Renal Cell Cancer ◽

Liquid Biopsy ◽

Renal Cell ◽

Large Scale ◽

Cell Cancer ◽

Serum Markers ◽

New Drugs ◽

Patient Change

purpose: Liquid biopsy is becoming increasingly important as a guide for selecting new drugs and determining their efficacy. In urological cancer, serum markers for renal cell and urothelial cancers has made the development of liquid biopsy for these cancers strongly desirable. Liquid biopsy is less invasive than conventional tissue biopsy is, enabling frequent biopsies and, therefore, is considered effective for monitoring the treatment course. Circulating tumor cells (CTCs) are a representative liquid biopsy specimen. In the present study, we focused on developing our novel technology for capturing renal cell cancer (RCC)-CTCs using an anti-G250 antibody combined with new devices. Basic experiments of our technology showed that it was possible to detect RCC-CTC with a fairly high accuracy of about 95%. Also, RCC-CTC was identified in the peripheral blood of actual RCC patients. Additionally, during the treatment course of the RCC patient, change in the number of RCC-CTC was confirmed in one case. We believe that the technology we developed will be useful for determining the treatment efficacy and drug selection for the treatment of renal cell cancer (RCC). In order to solve issues such as thresholds setting of this technology, large-scale clinical trials are expected.

Download Full-text

Diagnostic and Prognostic Value of Circulating Tumor Cells in Renal Cell Cancer: A systematic review and Meta-analysis

10.37766/inplasy2020.9.0007 ◽

2020 ◽

Author(s):

Liang Cao ◽

Dong Lin ◽

Tinghui Hu ◽

Xiaoxi Mou ◽

Hai Liao ◽

...

Keyword(s):

Systematic Review ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Renal Cell Cancer ◽

Renal Cell ◽

Prognostic Value ◽

Meta Analysis ◽

Cell Cancer ◽

Diagnostic And Prognostic Value

Download Full-text

Tumor Size is a Determinant of the Rate of Stage T1 Renal Cell Cancer Synchronous Metastasis

The Journal of Urology ◽

10.1016/j.juro.2009.06.018 ◽

2009 ◽

Vol 182 (4) ◽

pp. 1287-1293 ◽

Cited By ~ 43

Author(s):

Giovanni Lughezzani ◽

Claudio Jeldres ◽

Hendrik Isbarn ◽

Paul Perrotte ◽

Shahrokh F. Shariat ◽

...

Keyword(s):

Renal Cell Cancer ◽

Tumor Size ◽

Renal Cell ◽

Cell Cancer ◽

Synchronous Metastasis ◽

Stage T1

Download Full-text

Phase II Trial of Autologous Tumor Vaccination, Anti-CD3-Activated Vaccine-Primed Lymphocytes, and Interleukin-2 in Stage IV Renal Cell Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2003.08.023 ◽

2003 ◽

Vol 21 (5) ◽

pp. 884-890 ◽

Cited By ~ 69

Author(s):

Alfred E. Chang ◽

Qiao Li ◽

Guihua Jiang ◽

Donna M. Sayre ◽

Thomas M. Braun ◽

...

Keyword(s):

Cell Therapy ◽

Lymph Nodes ◽

Tumor Cells ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer ◽

Interleukin 2 ◽

Stage Iv ◽

Autologous Tumor ◽

Cytokine Release

Purpose: Previous preclinical and clinical studies have demonstrated that autologous tumor vaccines can induce relatively specific tumor-reactive T cells in draining lymph nodes. The adoptive transfer of these cells can result in tumor regression. Patients and Methods: Patients with stage IV renal cell cancer (RCC) were vaccinated with irradiated autologous tumor cells admixed with Calmette-Guérin bacillus. Approximately 7 days later, vaccine-primed lymph nodes (VPLNs) were harvested and the lymphoid cells secondarily activated with anti-CD3 monoclonal antibody and expanded in interleukin 2 (IL-2). The activated cells were subsequently infused intravenously along with the concomitant administration of bolus IL-2 (360,000 U/kg intravenously × 15 doses). Results: Thirty-nine patients were entered onto the study, of whom 34 completed an initial course of cell therapy consisting of a mean (SEM) number of 4.3 (2.2) × 1010 VPLN cells. Among subjects who received cell therapy, there were nine responses (four complete responses [CRs] and five partial responses [PRs]), for an overall response rate of 27%. The durations of the CRs were > 48, 45, > 35, and 12 months, and the durations of the PRs were > 63, 48, 15, 12, and 4 months. Cultured tumor cells were available to assess in vitro cytokine release of VPLN cells in 24 subjects. The median cytokine release ratio of interferon gamma (IFNγ) to IL-10 for responders and nonresponders was 992 and 5, respectively, which was significantly different (P = .047). Conclusion: The treatment protocol resulted in durable tumor responses in patients with advanced RCC. The ratio of IFNγ and IL-10 cytokines released in response to tumor by the VPLN cells was a significant correlate with tumor response.

Download Full-text